Janssen Pharmaceutica NV: Janssen Announces Treatment with ERLEADA?(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
FOR EMEA PHARMACEUTICAL TRADE AND MEDICAL MEDIA ONLY NOT FOR DISTRIBUTION IN BENELUX, SWEDEN AND ITALY
Janssen Pharmaceutica NV (Janssen) announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of apalutamide plus androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) when compared to placebo plus ADT.
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11 9:30 PM-10:15 PM CET).
Date Time
Researcher identifies way to prevent breast cancer stem-like cells from evading therapy
New research at the University of Alberta has revealed a way to increase the sensitivity to immunotherapy of a rare type of cells within a tumour that are responsible for treatment resistance and breast cancer progression. The study, recently published in the journal Cancer Letters, could pave the way to better treatment outcomes for patients.
The researchers looked at how to use a type of cell called gamma delta T-cells more effectively in immunotherapy to target breast cancer stem-like cells. T-cell immunotherapy is a promising new field, with researchers around the world working to develop treatments that use a patient’s own immune system to fight diseases such as cancer. However, most immunotherapy of this type focuses on the more conventional alpha beta T-cells.
Sensormatic Solutions Continues to Power Retail With Google Cloud
The two companies strategic partnership continues to innovate and solve real-world challenges for the evolving retail industry Johnson Controls, the global leader for smart, healthy and sustainable buildings and the architect of OpenBlue connected solutions, today announced that Sensormatic Solutions, its leading global retail solutions portfolio, continues to innovate through its partnership and joint investment with Google Cloud.
The long-term strategic partnership is helping to power Sensormatic IQ, the new intelligent operating platform for retail, delivering improved shopper experiences and retail outcomes as the industry continues to evolve and meet new challenges. The Google Cloud-based platform offers the flexibility and scalability retailers need to make prescriptive, data-driven decisions about operations from headquarters to the individual store-level. Google Cloud offered Sensormatic and its retai